Novo Nordisk closes on EU okay for haemophilia antibody
Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia.
Gilead, MSD say HIV combo could be weekly, oral HIV drug
In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients
Roche trial confirms Vabysmo efficacy in minorities
A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African American, Black, Hispanic and Latino, plugging a gap in the dat
PursueCare brings Pear addiction DTx apps back to life
Two pioneering digital therapeutics (DTx) for addiction are available once again after their original developer Pear Therapeutics was dissolved last year.
FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug
At its second attempt, Astellas has won FDA approval for its first-in-class cancer therapy, Vyloy, which got the green light for certain gastric cancers.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
BIO-Europe's 30th Anniversary Landmark Event in Stockholm
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and
8th Dermatology Drug Development Summit
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
7th RNA-Targeted Drug Discovery & Development Summit
Optimizing Lead Discovery, Structural Analysis & Preclinical Modeling to Successfully Develop Stable, Effective & Orally Bioavailable Small Molecule RNA Drugs for Robust Translation
9th CDD For Biologics Summit 2024
Integrate Computational Biology, Generative AI & Machine Learning to Revolutionize Biologics Drug Discovery & Development
Targeted Radiopharmaceuticals Summit EU 2024
Taking place in Amsterdam 3rd- 5th December! With 40+ new speakers, 2 tracks of content (pre-clinical and clinical), a deep dive workshop day